Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET.  The meeting is taking place October 15-19 in Vienna, Austria.  The data will also be published in the December issue of United European Gastroenterology Journal, a peer-reviewed medical journal providing coverage of both translational as well as clinical studies from all fields of gastroenterology.(Original Source)

Shares of Arena Pharmaceuticals closed yesterday at $1.86. ARNA has a 1-year high of $2.68 and a 1-year low of $1.30. The stock’s 50-day moving average is $1.65 and its 200-day moving average is $1.73.

On the ratings front, Arena has been the subject of a number of recent research reports. In a report issued on September 14, FBR analyst Christopher James initiated coverage with a Buy rating on ARNA and a price target of $6, which represents a potential upside of 222.6% from where the stock is currently trading. Separately, on August 10, Needham’s Alan Carr maintained a Hold rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Christopher James and Alan Carr have a total average return of -10.9% and 14.1% respectively. James has a success rate of 38% and is ranked #4029 out of 4184 analysts, while Carr has a success rate of 51% and is ranked #143.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers a range of drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases.